Finvest
PFE Pharmaceuticals · Large cap · Drugmaker · Healthcare · Thesis updated July 12, 2026

Pfizer’s rebound still has cliff risk

01 Running thesis

A better quarter, not a free pass

Pfizer’s latest update helped the bull case. In Q1 2026, total revenue excluding Comirnaty and Paxlovid grew 7% operationally. Launched and acquired products grew 22% operationally. That is real proof that the company is not only waiting for COVID-19 demand to come back.

Cancer is the clearest bright spot. Seagen assets grew 20% in the quarter, and Padcev revenue grew 39%. Pfizer also has a bigger long-term shot in obesity, with 10 planned Phase 3 studies for berobenatide and first approvals targeted for 2028.

The bear case did not go away. Pfizer still expects a significant revenue hit from patent and regulatory exclusivity losses from 2026 through 2030. Vyndamax helps because its patent exclusivity now extends to 2031, but other large products still need to be replaced.

Finn’s view is cautious. The company looks cheaper than many faster growers, but growth and recent performance still score poorly. For the stock to work, Pfizer needs Seagen, new launches, obesity data, and cost cuts to land while pricing and tariff risk stay manageable.

May 2026Q1 2026 gave the bull case real support. The non-COVID business grew 7% operationally, launched and acquired products grew 22%, and Seagen assets grew 20%.
May 2026Pfizer’s Q1 2026 filing added a new tariff risk. Section 232 tariffs on imported patented drugs and ingredients could phase in starting July 31, 2026, with the final impact still unknown.
Feb 2026The 2025 Form 10-K made the patent cliff risk more concrete. Pfizer said it expects a significant revenue reduction from exclusivity expirations in 2026 through 2030.
Nov 2025IRA pricing pressure became more visible in Pfizer’s Q3 2025 filing. The company cited higher manufacturer discounts as a drag on net prices for products including Vyndaqel and Ibrance.
Aug 2025The initial thesis framed Pfizer as a large drugmaker in transition. Growth from Vyndaqel, Padcev, Eliquis, Abrysvo, and other products was set against COVID-19 declines, IRA pressure, and the coming patent cliff.
02 Business model

Patents turn science into cash

Pfizer makes money by discovering, developing, making, and selling medicines and vaccines. The best years for a drug are usually when patents protect it from cheap copycat drugs. After patents expire, generic or biosimilar rivals can push sales and prices down fast.

The company spends heavily on research and development. It also buys or licenses drugs from other companies when it wants to add growth faster than its own labs can provide it. Seagen is the current example, giving Pfizer a larger cancer drug base.

The model breaks when old blockbusters fade before new ones are ready. That is Pfizer’s core test now. Management is also cutting costs and optimizing manufacturing to improve margins, but cost cuts alone cannot solve a patent cliff.

03 Product portfolio

The drugs that matter most

Cash cow

Vyndaqel family and Vyndamax

These heart drugs are key revenue drivers. An April 2026 legal settlement extended Vyndamax patent exclusivity to 2031, which gives Pfizer more cash flow visibility.

Cash cow

Eliquis

Eliquis is a major blood thinner sold with a partner. It faces Medicare price negotiation pressure under the IRA, with a new Medicare price required from January 1, 2026.

Growth engine

Padcev and Seagen oncology assets

Cancer is becoming Pfizer’s main growth engine. Padcev revenue grew 39% in Q1 2026, while Seagen assets grew 20% in the quarter.

Steady

Prevnar family

Prevnar vaccines are part of Pfizer’s broad vaccine base. They help diversify the business beyond cancer and specialty drugs.

Steady

Ibrance and Xtandi

These are important cancer products, but the older portfolio faces pricing and exclusivity pressure. Ibrance has also been cited as affected by IRA-related manufacturer discounts.

Cash cow

Comirnaty and Paxlovid

The COVID-19 vaccine and antiviral still matter, but demand is falling from pandemic highs. Pfizer’s core story now depends more on non-COVID growth.

Option

Berobenatide

This obesity drug is a long-term option. Pfizer plans 10 Phase 3 studies and is targeting first approvals in 2028.

04 Business segments

One segment, two big markets

United States revenue59%flat
International revenue41%flat

Pfizer reports Biopharma as its sole reportable segment. The mix shown uses 2025 geographic revenue: U.S. revenue was $37.1 billion and International revenue was $25.5 billion, out of total revenue of $62.6 billion.

05 Risk factors

What could still break

Patent cliff hits faster than launches grow

High impact · High odds

Pfizer expects a significant revenue reduction from patent and regulatory exclusivity losses in 2026 through 2030. Vyndamax protection to 2031 helps, but it does not protect the whole company. If new products fail to scale, revenue can shrink even if the science looks promising.

We watchWatch management’s updates on 2026 through 2030 exclusivity losses and growth from launched and acquired products.

Section 232 tariffs cut margins

High impact · Medium odds

The U.S. government announced Section 232 tariffs on imported patented pharmaceuticals and ingredients in April 2026. Duties could be up to 100% and are set to phase in starting July 31, 2026. Pfizer may get exemptions tied to U.S. manufacturing investment, but the final cost is still unknown.

We watchWatch for company guidance on tariff impact in dollars or margin basis points.

Drug pricing pressure lowers net prices

High impact · High odds

The IRA is already hitting net prices through Medicare changes and manufacturer discounts. Eliquis is among the first drugs subject to Medicare price negotiation. The OBBBA could add more pressure by reducing federal healthcare spending and increasing price controls.

We watchWatch net price comments for Eliquis, Vyndaqel, Ibrance, and other Medicare-exposed products.

Seagen integration disappoints

Medium impact · Medium odds

Seagen is now central to Pfizer’s growth plan. The early numbers are strong, with Seagen assets growing 20% in Q1 2026, but acquisitions can still miss on cost savings, sales execution, or pipeline timing. Pfizer needs the deal to keep working.

We watchWatch Seagen asset growth, synergy updates, and oncology launch momentum.

Pipeline data fails to replace old drugs

High impact · Medium odds

Drug development is risky, and Pfizer needs wins. The company expects 8 major data readouts in 2026, including atirmociclib, and plans 10 Phase 3 obesity studies for berobenatide. A few weak readouts could make the patent cliff harder to offset.

We watchWatch 2026 data readouts, especially atirmociclib, plus berobenatide trial starts and designs.
06 Quick answers

In one breath

Why is Pfizer stock still under pressure after Q1 2026?

The quarter showed better non-COVID growth, but investors are still worried about the 2026 through 2030 patent cliff. Pricing rules, possible tariffs, and fading COVID-19 demand also weigh on the stock.

What is the biggest bull case for Pfizer?

The bull case is that Pfizer’s post-COVID rebuild is starting to work. Non-COVID revenue grew 7% operationally in Q1 2026, Seagen assets grew 20%, and Vyndamax patent exclusivity now runs to 2031.

What is Seagen doing for Pfizer?

Seagen gives Pfizer a stronger cancer drug portfolio. Its assets grew 20% in Q1 2026, which makes the deal one of the clearest growth drivers in the current story.

What should investors watch next?

Watch Section 232 tariff guidance, Seagen growth, 2026 pipeline readouts, and the start of berobenatide Phase 3 obesity studies. These will show whether Pfizer can offset its patent losses.